Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.74 |
| ▸ | PKM | P14618 | 3/20 | 0.74 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.73 |
| ▸ | IL1RN | P18510 | 1/20 | 0.73 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.73 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.73 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.73 |
| ▸ | CA1 | P00915 | 2/20 | 0.68 |
| ▸ | CA2 | P00918 | 2/20 | 0.68 |
| ▸ | CA12 | O43570 | 1/20 | 0.65 |
| ▸ | CA9 | Q16790 | 1/20 | 0.65 |
| ▸ | AR | P10275 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | PGR | P06401 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5794629 | 0.98 | ALDH1A1 (0.71) | ALDH1A1MEN1KMT2APKMKEAP1 | |
| SCHEMBL8176212 | 0.92 | KMT2A (0.74) | ALDH1A1MEN1KMT2APKMKEAP1 | |
| SCHEMBL28411679 | 0.92 | KMT2A (0.74) | ALDH1A1MEN1KMT2APKMKEAP1 | |
| SCHEMBL7501950 | 0.90 | CA1 (0.81) | ALDH1A1MEN1KMT2APKMFFAR4 | |
| SCHEMBL810795 | 0.89 | KMT2A (0.91) | ALDH1A1MEN1KMT2APKMKEAP1 | |
| Hydrochloric Acid SCHEMBL5797806 | 0.88 | CA1 (0.79) | ALDH1A1MEN1KMT2APKMFFAR4 | |
| SCHEMBL9001182 | 0.85 | KMT2A (1.00) | ALDH1A1MEN1KMT2APKMKEAP1 | |
| SCHEMBL25031372 | 0.85 | KEAP1 (1.00) | ALDH1A1MEN1KMT2APKMKEAP1 | |
| Phenyl(Phenylsulfonyl)Amine SCHEMBL114765 | 0.85 | KEAP1 (1.00) | ALDH1A1MEN1KMT2APKMKEAP1 | |
| SCHEMBL13167612 | 0.83 | KMT2A (0.80) | ALDH1A1MEN1KMT2APKMKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109937210-B | Agents, uses and methods for treating synucleinopathies | H.隆德贝克有限公司 | 2023-09-15 | — | — | CN | claimed |
| EP-2382191-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | Abbott Laboratories, Inc. (US) | 2011-11-02 | — | — | EP | claimed |
| EP-1651595-A2 | UBIQUITIN LIGASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2006-05-03 | — | — | EP | claimed |
| WO-2005007621-A2 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | claimed |
| US-12553889-B2 | Small molecules targeting the intrinsically disordered structural ensemble of α-synuclein protect against diverse α-synuclein mediated dysfunctions | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-17 | — | — | US | disclosed |
| US-12421303-B2 | Agents, uses and methods for the treatment of synucleinopathy | H. LUNDBECK A/S (DK) | 2025-09-23 | — | — | US | disclosed |
| US-20240034992-A1 | DOPAMINERGIC NEURONS COMPRISING MUTATIONS AND METHODS OF USE THEREOF | FUJIFILM Cellular Dynamics, Inc. (US) | 2024-02-01 | — | — | US | disclosed |
| CN-109937210-B | Agents, uses and methods for treating synucleinopathies | H.隆德贝克有限公司 | 2023-09-15 | — | — | CN | disclosed |
| US-20220155287-A1 | SMALL MOLECULES TARGETING THE INTRINSICALLY DISORDERED STRUCTURAL ENSEMBLE OF ALPHA-SYNUCLEIN PROTECT AGAINST DIVERSE ALPHA-SYNUCLEIN MEDIATED DYSFUNCTIONS | UNIV CALIFORNIA (US) | 2022-05-19 | — | — | US | disclosed |
| EP-3941452-A1 | SMALL MOLECULES TARGETING THE INTRINSICALLY DISORDERED STRUCTURAL ENSEMBLE OF ALPHA-SYNUCLEIN PROTECT AGAINST DIVERSE ALPHA-SYNUCLEIN MEDIATED DYSFUNCTIONS | The Regents of the University of California (US) | 2022-01-26 | — | — | EP | disclosed |
| WO-2020190970-A1 | SMALL MOLECULES TARGETING THE INTRINSICALLY DISORDERED STRUCTURAL ENSEMBLE OF ALPHA-SYNUCLEIN PROTECT AGAINST DIVERSE ALPHA-SYNUCLEIN MEDIATED DYSFUNCTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-24 | — | — | WO | disclosed |
| CN-108822002-B | Method for synthesizing N-aryl sulfonamide under assistance of ultrasonic waves | 中南大学 | 2020-05-05 | — | — | CN | disclosed |
| US-20180022699-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | PURDUE PHARMA L.P. | 2018-01-25 | — | — | US | disclosed |
| CN-106674200-A | Compound containing L-prolinamide fragment, and preparation method and application thereof | 西安交通大学 | 2017-05-17 | — | — | CN | disclosed |
| US-20160326111-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | PURDUE PHARMA LP (US) | 2016-11-10 | — | — | US | disclosed |
| US-9212139-B2 | Aryl substituted indoles and their use as blockers of sodium channels | PURDUE PHARMA, L.P. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20130296281-A1 | Aryl Substituted Indoles and Their Use as Blockers of Sodium Channels | PURDUE PHARMA L.P. (US) | 2013-11-07 | — | — | US | disclosed |
| EP-2382191-A1 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS | Abbott Laboratories, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-1239852-A2 | BISSULFONAMIDE DERIVATIVES AS ENZYME INHIBITORS | Arrow Therapeutics Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001028537-A2 | BISSULFONAMIDE DERIVATIVES AS ENZYME INHIBITORS | ARROW THERAPEUTICS LIMITED (GB) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220155287-A1 | SMALL MOLECULES TARGETING THE INTRINSICALLY DISORDERED STRUCTURAL ENSEMBLE OF ALPHA-SYNUCLEIN PROTECT AGAINST DIVERSE ALPHA-SYNUCLEIN MEDIATED DYSFUNCTIONS | SNCA, PARK7, SYNCRIP | ALDH1A1 3157/4885MEN1 4169/4885KMT2A 4281/4885 |
| US-20130296281-A1 | Aryl Substituted Indoles and Their Use as Blockers of Sodium Channels | SCN5A, TRPV1, TRPV5 | ALDH1A1 588/4885MEN1 1936/4885KMT2A 1696/4885 |
| US-20160326111-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | TRPC5, TRPV5, TRPV1 | ALDH1A1 559/4885MEN1 2007/4885KMT2A 1515/4885 |
| US-20180022699-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | TRPC5, TRPV5, TRPV1 | ALDH1A1 559/4885MEN1 2007/4885KMT2A 1515/4885 |
| US-12553889-B2 | Small molecules targeting the intrinsically disordered structural ensemble of α-synuclein protect against diverse α-synuclein mediated dysfunctions | SNCA, PARK7, HTT | ALDH1A1 3505/4885MEN1 4577/4885KMT2A 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.